

Intraperitoneal (IP) Gentamicin

Indication	Peritoneal Dialysis (PD) Peritonitis																				
Dose	Initial dose 0.6mg/kg (actual body weight) then subsequent doses adjusted according to blood levels. NB: IP gentamicin can be used once daily (if patient is admitted to hospital), but should be given in the long dwell only (refer to Trust PD Peritonitis protocol).																				
Preparation	Gentamicin ampoules are available as either: 20mg/2ml injections (= 10mg/ml) or 80mg/2ml injections (= 40mg/ml) 1. Please select the most appropriate strength that will allow ease of measurability of the dose required. 2. Using a filter needle and syringe, withdraw the required dose of gentamicin.																				
Administration	To be added to the dialysis fluid in the long dwell only (day dwell for APD and overnight dwell for CAPD).																				
Shelf-life	The product should be used immediately.																				
Additional information	There is an increased risk of ototoxicity when gentamicin is used with teicoplanin. Warn patients of this potential side-effect and ask them to report any changes to or loss of hearing. NB: Aminoglycosides (e.g. gentamicin) and teicoplanin solutions are incompatible and must not be mixed for injection; however, they are compatible in dialysis fluid and may be freely used in the treatment of CAPD-related peritonitis.																				
Monitoring	Monitor auditory function, particularly if patient is also on other ototoxic/ nephrotoxic medications e.g. teicoplanin or furosemide. Levels of gentamicin should initially be measured 1 day after starting regular treatment, and thereafter as necessary (typically every 3 days). (Refer to Trust PD Peritonitis protocol).																				
Sample Label	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="4" style="text-align: center; background-color: yellow;">DRUGS ADDED TO THIS INFUSION</th> </tr> <tr> <td colspan="3" style="text-align: center; background-color: yellow;">PATIENT <i>A. Patient (A. Number)</i></td> <td style="text-align: center; background-color: yellow;">WARD <i>407</i></td> </tr> <tr> <td style="text-align: center; background-color: yellow;">DRUG <i>IP gentamicin 10.1ml</i></td> <td style="text-align: center; background-color: yellow;">AMOUNT <i>40mg</i></td> <td style="text-align: center; background-color: yellow;">ADDED BY</td> <td style="text-align: center; background-color: yellow;">CHECK BY</td> </tr> <tr> <td style="text-align: center; background-color: yellow;">DATE ADDED TIME ADDED</td> <td colspan="2" style="text-align: center; background-color: yellow;">EXP. DATE EXP. TIME</td> <td style="text-align: center; background-color: yellow;">BATCH No.</td> </tr> <tr> <th colspan="4" style="text-align: center; background-color: yellow;">DISCONTINUE IF CLOUDINESS OR PRECIPITATE DEVELOPS</th> </tr> </table>	DRUGS ADDED TO THIS INFUSION				PATIENT <i>A. Patient (A. Number)</i>			WARD <i>407</i>	DRUG <i>IP gentamicin 10.1ml</i>	AMOUNT <i>40mg</i>	ADDED BY	CHECK BY	DATE ADDED TIME ADDED	EXP. DATE EXP. TIME		BATCH No.	DISCONTINUE IF CLOUDINESS OR PRECIPITATE DEVELOPS			
DRUGS ADDED TO THIS INFUSION																					
PATIENT <i>A. Patient (A. Number)</i>			WARD <i>407</i>																		
DRUG <i>IP gentamicin 10.1ml</i>	AMOUNT <i>40mg</i>	ADDED BY	CHECK BY																		
DATE ADDED TIME ADDED	EXP. DATE EXP. TIME		BATCH No.																		
DISCONTINUE IF CLOUDINESS OR PRECIPITATE DEVELOPS																					

**Written by: Maya Daas (Advanced Pharmacist – Renal Services)
Nov 2021**

**Checked by: James Kerr (Divisional Lead Pharmacist – Medicine)
Nov 2021**

Approved by: Nick Selby (Lead Renal Consultant)

For review: Nov 2023

Key contact: Advanced Pharmacist – Renal Services

References

SmPC – SNAOFI. Oct 2021. SPC Cidomycin 80 mg/2 ml Solution for Injection. Accessed via: www.medicines.org.uk/emc on 12/11/21.

Medusa monograph: Gentamicin. Accessed via <http://medusa.wales.nhs.uk> on 12/11/2021